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Purpose: To evaluate the impact of a community-based pharmacist-led face-to-face counseling 
program on medication adherence for patients who were new to therapy (NTT) for statin 
medications.
Patients and methods: This retrospective cohort study evaluated a program that was 
implemented in 76 national community pharmacies located in the midwest USA. It consisted 
of two face-to-face patient counseling sessions with a pharmacist that addressed patient barriers 
to adherence. A group of 2056 NTT statin patients was identified between September 1, 2010 
and October 31, 2010, and was followed for 12 months. The intervention group consisted of 
586 patients, and the comparison group comprised 516 patients. Outcomes were measured 
using the continuous medication possession ratio (MPR), categorical MPR, and medication 
persistency.
Results: After adjusting for covariates, the intervention group had statistically greater MPR 
than the comparison group at every month measured. For example, at 12 months the intervention 
group had a MPR of 61.8% (CI, 54.5%–69.2%) and the comparison group had a MPR of 56.9% 
(CI, 49.5%–64.3%); this 4.9% difference is significant (P , 0.01). The 12 month categorical 
MPR also showed significant differences between groups (Χ 2 = 6.12, P , 0.05); 40.9% of the 
intervention group and 33.7% of comparison group had a MPR greater than or equal to 80%. 
Finally, the intervention group had significantly greater persistency with their medication therapy 
than the comparison group at 60, 90, 120, and 365 days.
Conclusion: Patients who participated in brief face-to-face counseling sessions with a 
community pharmacist at the beginning of statin therapy demonstrated greater medication 
adherence and persistency than a comparison group. This brief targeted intervention at 
the initiation of maintenance drug therapy moderates the high risk of nonadherence and 
discontinuation; it helps patients establish a routine of daily self-medication and potentially 
improves their long-term clinical outcomes.
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Introduction
Nonadherence to medication therapy is a problem faced by many patients with chronic 
conditions.1,2 It is estimated that more than 25% of  patients in the USA are nonadherent 
with their prescribed medications.3 With over 133 million Americans, almost half of 
adults, living with at least one chronic condition, this problem is costly in terms of 
morbidity, mortality and health care budgets.4–7 In 2009, the annual cost of nonadher-
ence in the USA was estimated at USD$290 billion.8
Hypercholesterolemia is one of the most common chronic conditions, 
affecting over 33.5 million adults in the USA, and it is a significant risk factor for 
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cardiovascular disease.9,10 For some patients, it can be managed 
with improvements to diet and exercise; but for many others, 
additional medication therapy such as statin drugs, is required 
to lower cholesterol levels.11,12 Unfortunately, many patients 
are nonadherent to statin medications.9 It has been reported 
that medical costs and risk of hospitalization for patients with 
hypercholesterolemia whose medication adherence rates were 
less than 80%, were significantly higher than for those with 
adherence rates of 80% and greater.7
Nonadherence may be driven by a myriad of factors that 
can be practical and behavioral. These factors include personal 
beliefs/environment, sociodemographic characteristics, 
disease state, comorbidities, health status, cost factors, patient 
perception of drug therapy value, issues related to drug 
regimen complexity and side effects, health literacy, and poor 
communication with health professionals.13–17 For example, 
a survey of patients with poor adherence to antihypertensive 
drug therapy in a managed care setting found that simple 
forgetfulness and being too busy were the most common 
reasons given for poor adherence.18
Community pharmacists are well positioned to help 
patients overcome barriers to adherence. Several studies 
demonstrate that patient counseling by community 
pharmacists can improve persistence, adherence, self-care, 
and in some cases yield a net economic return.7,19–22 For 
example, Project ImPACT showed that for patients with 
poorly controlled lipid disorders, counseling by pharmacists 
in community pharmacy settings can improve persistence 
and adherence with drug therapy, and improve lipid levels.19 
In the Asheville Program, a multi-year study involving 
consultation for diabetic patients with community-based 
pharmacists, glycosylated hemoglobin (A1C) values 
and lipid levels improved, medical costs decreased and 
worker productivity increased.20 The Ten City Challenge 
demonstrated that community pharmacist-provided diabetes 
patient coaching results in greater patient engagement in 
self-care and improved process of care indicators including 
A1C, influenza vaccinations, systolic and diastolic blood 
pressure, lipid profiles and percentage of patients receiving 
foot and eye examinations.21 Finally, a systematic review 
of the published literature found pharmacist face-to-face 
interventions performed in community pharmacy settings 
to be more effective than other types of interventions at 
improving patient adherence to medication therapy.22
The objective of the present study was to assess the 
impact of a community-based pharmacist-led face-to-face 
counseling program on medication adherence for patients 
who were new to therapy with statin medications.
Methods
We conducted a retrospective cohort study to evaluate a 
program designed to improve medication adherence and 
persistency among patients who were new to therapy (NTT) 
for statin medications. Patients were defined as NTT if the 
patient had no evidence of a filled prescription in the statin 
therapeutic class during the previous 15 months. The program 
was implemented in 76 national community pharmacies 
located in a major metropolitan area in the Midwest. The 
program consisted of two face-to-face patient counseling 
sessions with a clinical pharmacist.
All 214 licensed pharmacists providing interventions 
received 2 hours of additional training via an interactive 
webinar. The training focused on brief motivational 
interviewing techniques for addressing patient barriers to 
adherence. It also included practical techniques on how 
to fit the counseling sessions into their existing pharmacy 
workflow.
Patient selection
When a patient submitted a prescription for a statin medication 
and was identified by the pharmacy data system as NTT, the 
system notified the pharmacist to offer the patient a first fill 
face-to-face counseling session. The first session consisted 
of motivational interviewing to determine the patient’s 
confidence and commitment to following the prescribed 
treatment regimen as well as discussion about fitting 
medications into their daily routine. Patients who completed 
the initial counseling session and who were not excluded due 
to self-report of prior use of statins were automatically eligible 
for a follow-up counseling session to be completed at their 
second fill. The pharmacy data system notified the pharmacist 
to offer a second counseling session that reinforced messages 
from the first session; the pharmacist inquired about the 
patient’s experience during the first month of treatment and 
focused on removing any barriers to adherence. On average, 
the new to therapy conversation lasted 3 to 5 minutes, and 
follow-up conversations were 1 to 2 minutes in length.
Patients who filled their initial statin prescription and 
received both face-to-face first fill and second fill counseling 
sessions that were less than 6 months apart were included 
in the intervention group. Targeted NTT patients who filled 
their initial statin prescription during the study period but did 
not receive any face-to-face counseling were included in the 
comparison group. Comparison group patients did not receive 
consultations due to various reasons such as caregivers pick-
ing up the prescription, use of drive through prescription 
pick-up, or did not have time to wait for consultation during 
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busy hours. In addition, to align with the criteria applied to 
the intervention group, patients in the comparison group were 
required to have at least two filled prescriptions and the first 
and second fill had to occur less than 6 months apart.
A group of 2056 patients who were NTT for statin 
medication between September 1, 2010 and October 31, 2010 
were followed for 12 months after their initial identification 
date. Eligibility criteria included NTT patients who filled 
an initial 30-day quantity of statin medication. There was 
no quantity restriction for refills; so some patients may 
have refilled with 90-day quantities. As detailed in Figure 1, 
out of 2056 NTT patients, 702 patients did not receive 
any intervention, while 476 patients received a first fill 
intervention but were not eligible for a second fill intervention 
due to prior use of statin medication. After applying inclusion 
and exclusion criteria, the intervention group consisted of 
586 patients and the comparison group included 516 patients. 
There were no statistically significant differences between 
the intervention and comparison groups in mean age, age 
bands, gender distribution, pharmaceutical benefit plan type, 
or co-pay amounts (Table 1). The average income level of 
patients, as determined by pharmacy trade area estimates, 
was not significantly different between groups (data not 
shown). Finally, there was no significant difference between 
the groups in comorbidities as measured by the number of 
unique therapeutic classes.
Outcome measures
Adherence was measured using the medication possession 
ratio (MPR), which was calculated by taking patients’ 
total days’ supply of statin medications during the 
observation period and dividing by total days during 
the observation period.23 Monthly MPR was calculated 
for an observation period starting with the initial fill and 
ending at the specified month; measurement continued until 
month 12. For overlapping prescriptions such as early refills, 
the start date of the refill was adjusted to the day after the 
prior prescription was exhausted. Similarly, if the due date of 
the last prescription was beyond the observational period, the 
due date of the last prescription was truncated to the end of 
the observational period. Additionally, a categorical MPR was 
used to compare the study groups at 365 days. We considered 
patients with an MPR of 80% or higher as adherent, and 
patients with an MPR less than 80% were nonadherent. The 
80% threshold is commonly used to imply “adherent” in 
medication adherence research.23
Persistency is the duration in days from the initiation to 
discontinuation of statin therapy during the follow-up period.23 
2056 eligible new to therapy 
statin patients
476 patients were excluded
from second fill intervention
due to prior use of a statin
878 patients eligible for second fill
intervention
186 patients did not
return for second fill
within 6 months
193 patients did not
return for second fill
within 6 months
99 patients received
second fill but bypassed
pharmacist consultation
Intervention group Comparison group
586 patients completed first and
second fill face-to-face pharmacist
consultations
516 patients had at least one 
subsequent stain Rx, but no
face-to-face pharmacist consultations
1354 patients provided face-to-face
pharmacist consultation at first fill
702 patients not provided face-to-face
pharmacist consultation at first fill
Figure 1 Patient selection.
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Table 1 Baseline characteristics of study groups
Intervention group   
(N = 586)
Comparison group   
(N = 516)
Patients, n % Patients, n %
Gender
Male 271 46 255 49
Female 315 54 261 51
Age, years
18–34 37 6 19 4
35–54 256 44 216 42
55–64 172 29 165 32
65+ 121 21 116 22
Mean (SD) years 54.2 (12.4) 56.0 (12.2)
Plan type
Commercial 441 75 378 73
government 141 24 135 26
Cash 4 1 3 1
Co-pay, USD
$0.00 79 13 68 13
$0–10 351 60 279 54
$10–20 63 11 72 14
$20–30 23 4 39 7
.$30 70 12 58 11
Therapeutic classes per patient
Mean (SD) 3.24 (1.99) 3.21 (1.96)
Note: There were no significant differences between groups on any descriptive 
variable.
Abbreviation: SD, standard deviation.
Table 2 Unadjusted medication possession ratio by study group and month
Follow-up  
period
Intervention group, %  
(95% CI) (N = 586)
Comparison group, %  
(95% CI) (N = 516)
Absolute  
difference, %
Relative  
difference, %
P value
2-month 87.6 (86.1–89.0) 84.8 (83.2–86.4) 2.8 3.3 ,0.05
3-month 83.0 (81.5–84.6) 80.2 (78.5–81.9) 2.8 3.5 ,0.05
4-month 79.4 (77.7–81.0) 75.8 (74.0–7.70) 3.5 4.6 ,0.01
5-month 76.5 (74.7–78.2) 73.2 (71.3–75.1) 3.3 4.5 ,0.05
6-month 74.2 (72.4–76.1) 70.7 (68.7–72.7) 3.5 4.9 ,0.05
7-month 72.1 (70.2–73.9) 68.4 (66.3–70.5) 3.7 5.4 ,0.05
8-month 70.3 (68.3–72.3) 66.3 (64.1–68.6) 3.9 6.0 ,0.01
9-month 68.4 (66.3–70.4) 64.4 (62.1–66.7) 3.9 6.2 ,0.05
10-month 66.7 (64.6–68.9) 62.6 (60.2–65.0) 4.0 6.5 ,0.05
11-month 65.2 (63.0–67.4) 60.8 (58.4–63.2) 4.4 7.2 ,0.01
12-month 63.5 (61.2–65.8) 58.9 (56.5–61.4) 4.4 7.5 ,0.01
Abbreviation: CI, confidence interval.
We measured persistency as the percentage of patients who 
had any available statin medication at 60, 90, and 120 days 
using a 15-day permissive gap. We also measured persistency 
at 365 days using a 60-day permissive gap. Patients were 
considered discontinued if they did not have a refill within 
the permissive gap. In a review of the persistency literature, 
Sikka et al reported that permissive refill gaps range from 
15 to 120 days, and there is little direction in the literature 
to determine the appropriate length of the gap.24 We used the 
shortest permissive gap in order to measure the early impact of 
the intervention; it essentially measures how quickly patients 
return to refill their medications. A larger permissive gap was 
also used to assess the long-term   persistency to medications.
Statistical analysis
The association between patient adherence and pharmacist 
face-to-face counseling was evaluated with a multivariate 
linear regression model including covariates of age, gender, 
number of therapeutic classes, insurance plan type (cash, 
commercial, government), and prescription co-pay amount 
measured in USD$10 bands between USD$0 and USD$30, 
and over USD$30. The regression model was repeated using 
monthly MPR results from 2 to 12 cumulative months to 
determine the relationship between the study groups and 
medication adherence. Student’s t-tests were calculated to 
determine the statistical significance of differences between 
unadjusted MPR group means. Chi-square tests were used 
to determine differences in proportions for categorical MPR 
and persistency. The P-value for statistical significance was 
set at α # 0.05. All analyses were conducted using SAS® 
Software (v 9.2; SAS Institute Inc, Cary, NC).
Results
The unadjusted MPR for the intervention group was 
significantly greater than the comparison group at every 
month measured (Table 2).
After adjusting for covariates, the regression model also 
showed that the intervention group had significantly greater 
MPR than the comparison group at every monthly period 
measured (Table 3 and Figure 2). Over time, both groups had 
decreasing MPR, however, the intervention group declined at 
a slower rate during most months. At the end of 12 months, the 
intervention group had an MPR of 61.8% and the comparison 
group had an MPR of 56.9%; this was an absolute difference 
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of 4.9% and a relative difference of 8.6% (intervention group 
MPR/comparison group MPR) (P , 0.01).
The categorical MPR showed that the intervention group 
had a significantly higher proportion of adherent patients 
(MPR $ 80%) than the comparison group. At 12 months, 
40.9% of the intervention group and 33.7% of the comparison 
group were adherent. The 7.2% difference between the groups 
was significant (Χ  2 = 6.12, P , 0.05).
The intervention group had greater initial persistency to 
their medication therapy than the comparison group (Table 4). 
Using a 15-day permissive gap, 79.5% of patients in the 
intervention group and 74.0% of patients in the comparison 
group were persistent at 60 days (Χ  2 = 4.66, P , 0.05). Using 
a 60-day permissive gap, 43.9% of patients in the intervention 
group and 38.2% of patients in the comparison group were 
persistent at 365 days (Χ 2 = 3.65, P = 0.05).
Discussion
Patients who participated in community pharmacist face-
to-face counseling sessions at the beginning of statin 
therapy demonstrate greater adherence and persistence 
to their medication therapy than a usual care comparison 
group. The pharmacists used motivational interviewing 
techniques in their counseling to help patients get a good 
start on their new medication. This method allowed patients 
to articulate their confidence and commitment to their 
new therapy and to address any perceived barriers to good 
adherence. In addition, the counseling helped patients learn 
to fit the medication into their daily routine. The initial 
gains in adherence, seen immediately after the counseling 
sessions, continued for 12 months. Over time, both groups 
had decreasing MPR, however the intervention group 
declined at a slower rate. The measure of persistency using 
Table 3 Adjusted medication possession ratio (MPR) by study group and month†
Follow-up  
period
Intervention group, %  
(95% CI) (N = 586)
Comparison group, %  
(95% CI) (N = 516)
Absolute  
difference, %
Relative  
difference, %
P-value
2-month 86.4 (81.7–91.1) 83.6 (78.9–88.3) 2.8 3.3 ,0.01
3-month 82.3 (77.3–87.4) 79.5 (74.5–84.6) 2.8 3.5 ,0.05
4-month 78.3 (72.8–83.7) 74.7 (69.2–80.1) 3.6 4.8 ,0.01
5-month 75.3 (69.7–81.0) 71.9 (66.3–77.6) 3.4 4.7 ,0.01
6-month 74.7 (68.8–80.7) 71.0 (65.0–77.0) 3.7 5.2 ,0.01
7-month 72.2 (65.9–78.5) 68.3 (62.0–74.6) 3.9 5.7 ,0.01
8-month 70.0 (63.5–76.6) 65.7 (59.2–72.3) 4.3 6.5 ,0.01
9-month 67.7 (60.9–74.5) 63.4 (56.6–70.2) 4.3 6.8 ,0.01
10-month 65.8 (58.8–72.8) 61.4 (54.3–68.4) 4.4 7.2 ,0.01
11-month 64.1 (56.9–71.3) 59.3 (52.1–66.5) 4.8 8.1 ,0.01
12-month 61.8 (54.5–69.2) 56.9 (49.5–64.3) 4.9 8.6 ,0.01
Note: †Adjusted MPR based on age, gender, payer type, co-pay amount, and number of therapeutic classes.
Abbreviation: CI, confidence interval.
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Figure 2 Adjusted† medication possession ratio (MPR) by study group and month.
Notes: †Adjusted MPR based on age, gender, payer type, co-pay amount, and number of therapeutic classes. *P , 0.05; **P , 0.01.
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a relatively short permissive gap of 15 days showed that 
patients in the intervention group refilled their prescriptions 
more quickly than the comparison group. However, the 
short permissive gap was too restrictive to measure the true 
persistency over time because it removes data for patients 
who are still on therapy but late to refill their medications. 
When we used a 60-day permissive gap, the groups 
were marginally, but significantly different at the end of 
12 months. Together these results show that the intervention 
had positive impact, however additional interventions may 
be needed, beyond the initial consultations, to reinforce the 
positive behavior change seen in the intervention group. 
While not measured in this study, improved adherence to 
statin therapy should lead to reductions in lipid levels and 
ultimately reductions in morbidity, mortality, and health 
care costs.7
These findings are similar to other studies demonstrating 
the impact of pharmacist interventions to improve medication 
adherence.19,25,26 Cutrona et al conducted a systematic review of 
randomized studies of various methods to improve medication 
adherence to a range of cardiovascular medications.22 They 
report that 5 out of 6 studies that measured comprehensive 
pharmacist interventions that included multiple session, blister 
packaging, and other tools, significantly improved medication 
adherence between 7%–27%.
The present study measured the impact of two brief 
counseling sessions on patients new to therapy for statin 
medications. Additional research is needed to independently 
validate these findings and determine whether they generalize 
to other therapeutic classes and chronic conditions. 
Furthermore, a multi-armed, randomized study design 
is recommended to compare the effectiveness of various 
adherence interventions and control for potential biases.
Limitations
This analysis utilized data from a single pharmacy chain and 
did not include data from other pharmacies. Furthermore, 
as with all studies using pharmacy claims data and MPR 
to determine adherence; it is not possible to determine 
whether the medications were actually taken as prescribed. 
Patients in the intervention group were counseled by different 
pharmacists at different stores; therefore, there was some 
uncontrolled variation in the intervention. Patients essentially 
self-selected into either the intervention or comparison 
group, which may have introduced some uncontrolled bias. 
However, the fact that the demographics and utilization 
characteristics of both groups are similar provides some 
assurance that the baseline group differences are minimal. 
Furthermore, we used a multivariate linear regression model 
including covariates of age, gender, number of therapeutic 
classes, insurance plan type, and prescription co-pay amount 
to minimize potential bias.
Conclusion
Patients who participated in brief face-to-face counseling 
sessions with a community pharmacist at the beginning of 
statin therapy demonstrate greater medication adherence and 
persistency than a comparison group. This brief intervention 
at the initiation of maintenance drug therapy moderates 
the high risk of nonadherence and discontinuation; it helps 
patients establish a routine of daily self-medication and 
potentially improves their long-term clinical outcomes.
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Table 4 Medication persistency between study groups
Persistency % of patients persistent Absolute difference, % Relative difference, % X  2 P-value
Intervention group, % Comparison group, %
60-day 79.5 74.0 5.5 7.4 4.66 ,0.05
90-day 64.0 56.6 7.4 13.1 6.29 ,0.05
120-day 52.7 46.3 6.4 13.8 4.51 ,0.05
365-day† 43.9 38.2 5.7 14.9 3.65         0.05
Note: †Use of a 60-day permissive gap, otherwise 15-day permissive gap.
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